Allergan taps CRISPR biotech Editas in eye care deal – BioPharma Dive
|
Allergan taps CRISPR biotech Editas in eye care deal
BioPharma Dive Intellia Therapeutics and CRISPR Therapeutics have both inked agreements delivering $75 million in upfront money, and Bayer has committed $300 million in funding for a joint venture with CRISPR Therapeutics. Other deals, including Editas' prior deal … |
